Zobrazeno 1 - 10
of 353
pro vyhledávání: ''
Autor:
Hiroki Ishihara, Takashi Ikeda, Hiroaki Shimmura, Toshio Takagi, Hideki Ishida, Kazunari Tanabe, Junpei Iizuka, Kazutaka Nakamura, Hidekazu Tachibana, Kazuhiko Yoshida, Hirohito Kobayashi, Hironori Fukuda, Yasunobu Hashimoto, Tsunenori Kondo, Yuki Nemoto
Publikováno v:
Targeted Oncology. 16:493-502
It remains unclear how early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events affects the outcome of previously untreated metastatic renal cell carcinoma (mRCC). To investigate the prognostic impact of the earl
Autor:
Shengmin Chen, Weifeng Wang, Huanliang Wu, Feng Yuan, Zhiren Lin, Gang Cheng, Shaohua Peng, Yunxiu Luo
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2913-2922
Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognos
Autor:
Mathijs A. Sanders, Mark van Duin, Pieter Sonneveld, Cyrus Khandanpour, Sabrin Tahri, Zoltán Kellermayer, Jessica Vermeulen, Davine Hofste op Bruinink, Pieter C. van de Woestijne, P. Koen Bos, Madelon de Jong, Remco Hoogenboezem, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Natalie Papazian
Publikováno v:
Nature Immunology, 22(6), 769-780. Nature Publishing Group
Progression and persistence of malignancies are influenced by the local tumor microenvironment, and future eradication of currently incurable tumors will, in part, hinge on our understanding of malignant cell biology in the context of their nourishin
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Anders Mellemgaard, Ghada F. Ahmed, Xiaoling Ou, Geoffrey R. Oxnard, Kiyotaka Yoh, Toyoaki Hida, Yuichiro Ohe, Hideo Saka, Manabu Hayama, Tomonori Hirashima, Ko Sugibayashi, Takayasu Kurata, Remy B. Verheijen
Publikováno v:
Targeted Oncology
Background Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Several studies have evaluated the role of delayed initiation of adjuvant chemotherapy (AC) in breast cancer (BC), but the results have remained controversial and an optimal time has not been defined. Our aim was to determine the effect of ti
Autor:
Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2145-2152
The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest
Autor:
Anke Bergmann, Marcelo Adeodato Bello, Luiz Claudio Santos Thuler, Isabella Cristina Santos Soares
Publikováno v:
Breast Cancer Research and Treatment. 187:547-555
Different tumor-related factors have been proposed to assess the risk of disease progression and death in women undergoing neoadjuvant breast cancer chemotherapy. Recently, besides the classical pre-treatment clinical stage (CS) and post-treatment pa
Autor:
Tatsuro Okamoto, Takashi Seto, Takatoshi Fujishita, Shinkichi Takamori, Mikako Jinnouchi, Mototsugu Shimokawa, Ryo Toyozawa, Masafumi Yamaguchi, Kensaku Ito, Taichi Matsubara
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:1857-1864
Pneumonitis can be triggered by anti-cancer therapies: cytotoxic chemotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors. There are few treatment options for patients who develop such pneumonitis and their treatment including chemo